Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

116 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
DNA topoisomerase I from human placenta.
Holden JA, Rolfson DH, Low RL. Holden JA, et al. Biochim Biophys Acta. 1990 Jul 30;1049(3):303-10. doi: 10.1016/0167-4781(90)90102-8. Biochim Biophys Acta. 1990. PMID: 2166581
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Gupta D, Holden J, Layfield L. Gupta D, et al. Appl Immunohistochem Mol Morphol. 2001 Mar;9(1):86-91. Appl Immunohistochem Mol Morphol. 2001. PMID: 11277421
Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Gupta D, Shidham V, Holden J, Layfield L. Gupta D, et al. Appl Immunohistochem Mol Morphol. 2000 Dec;8(4):267-74. Appl Immunohistochem Mol Morphol. 2000. PMID: 11127918
Human DNA topoisomerase II-alpha.
Martinchick J, Rahn M, Jolles C, Holden J. Martinchick J, et al. Int J Oncol. 1997 Jun;10(6):1229-34. doi: 10.3892/ijo.10.6.1229. Int J Oncol. 1997. PMID: 21533509
The anti-neoplastic and novel topoisomerase II-mediated cytotoxicity of neoamphimedine, a marine pyridoacridine.
Marshall KM, Matsumoto SS, Holden JA, ConcepciĆ³n GP, Tasdemir D, Ireland CM, Barrows LR. Marshall KM, et al. Among authors: holden ja. Biochem Pharmacol. 2003 Aug 1;66(3):447-58. doi: 10.1016/s0006-2952(03)00209-0. Biochem Pharmacol. 2003. PMID: 12907244
CD117, CK20, TTF-1, and DNA topoisomerase II-alpha antigen expression in small cell tumors.
Yang DT, Holden JA, Florell SR. Yang DT, et al. Among authors: holden ja. J Cutan Pathol. 2004 Mar;31(3):254-61. doi: 10.1111/j.0303-6987.2003.00175.x. J Cutan Pathol. 2004. PMID: 14984578
Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C, Holden JA, Tripp S, Layfield LJ. Willmore-Payne C, et al. Among authors: holden ja. Hum Pathol. 2005 May;36(5):486-93. doi: 10.1016/j.humpath.2005.03.015. Hum Pathol. 2005. PMID: 15948115
AK37: the first pyridoacridine described capable of stabilizing the topoisomerase I cleavable complex.
Marshall KM, Holden JA, Koller A, Kashman Y, Copp BR, Barrows LR. Marshall KM, et al. Among authors: holden ja. Anticancer Drugs. 2004 Oct;15(9):907-13. doi: 10.1097/00001813-200410000-00012. Anticancer Drugs. 2004. PMID: 15457132
Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
Coleman LW, Rohr LR, Bronstein IB, Holden JA. Coleman LW, et al. Among authors: holden ja. Hum Pathol. 2002 Jun;33(6):599-607. doi: 10.1053/hupa.2002.124911. Hum Pathol. 2002. PMID: 12152158
Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy.
Clayton F, Tessnow KA, Fang JC, Holden JA, Moore JG. Clayton F, et al. Among authors: holden ja. Mod Pathol. 2002 Nov;15(11):1191-6. doi: 10.1097/01.MP.0000032529.68297.B2. Mod Pathol. 2002. PMID: 12429798
116 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback